The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer

Brendon M. Stiles, Amit Bhargava, Prasad S. Adusumilli, Stephen F. Stanziale, Teresa H. Kim, Valerie W. Rusch, Yuman Fong

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.

Original languageEnglish (US)
Pages (from-to)357-364
Number of pages8
Issue number2
StatePublished - Aug 1 2003
Externally publishedYes

Bibliographical note

Funding Information:
Supported in part by US National Institutes of Health training grant T32 CA09501 (B.M.S.) and US Public Health Services grants R01CA75416 and R01CA72632 and MBC-99366 (Y.F.) from the American Cancer Society


Dive into the research topics of 'The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer'. Together they form a unique fingerprint.

Cite this